Skip to Content

Azelastine / fluticasone nasal Pregnancy and Breastfeeding Warnings

Azelastine / fluticasone nasal is also known as: Dymista

Medically reviewed on March 26, 2018.

Azelastine / fluticasone nasal Pregnancy Warnings

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

US FDA pregnancy category: C

Animal studies have revealed evidence of teratogenicity and other developmental toxic effects. There are no adequate and well-controlled studies in pregnant women.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Azelastine / fluticasone nasal Breastfeeding Warnings

A decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Dymista (azelastine-fluticasone nasal)." Meda Pharmaceuticals, Somerset, NJ.

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Dymista (azelastine-fluticasone nasal)." Meda Pharmaceuticals, Somerset, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide